Dimed SA Distribuidora de Medicamentos
BOVESPA:PNVL3

Watchlist Manager
Dimed SA Distribuidora de Medicamentos Logo
Dimed SA Distribuidora de Medicamentos
BOVESPA:PNVL3
Watchlist
Price: 9.75 BRL -1.02%
Market Cap: 1.5B BRL
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

PNVL3 Price Targets Summary
Dimed SA Distribuidora de Medicamentos

Wall Street analysts forecast PNVL3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PNVL3 is 12.58 BRL with a low forecast of 12.12 BRL and a high forecast of 13.65 BRL.

PNVL3 Lowest Forecast
Wall Street Target
12.12 BRL
24% Upside
PNVL3 Average Forecast
Wall Street Target
12.58 BRL
29% Upside
PNVL3 Highest Forecast
Wall Street Target
13.65 BRL
40% Upside
Lowest
Price Target
12.12 BRL
24% Upside
Average
Price Target
12.58 BRL
29% Upside
Highest
Price Target
13.65 BRL
40% Upside
Dimed SA Distribuidora de Medicamentos Competitors:
Price Targets
3141
Welcia Holdings Co Ltd
6% Downside
9627
AIN Holdings Inc
2% Downside
9989
Sundrug Co Ltd
24% Upside
PGMN3
Empreendimentos Pague Menos SA
31% Upside
3141
Welcia Holdings Co Ltd
6% Downside
9627
AIN Holdings Inc
2% Downside
9989
Sundrug Co Ltd
24% Upside
PGMN3
Empreendimentos Pague Menos SA
31% Upside
RDC
Redcare Pharmacy NV
103% Upside
FRAGUAB
Corporativo Fragua SAB de CV
161% Upside
9267
Genky DrugStores Co Ltd
11% Upside
RADL3
Raia Drogasil SA
28% Upside

Revenue
Forecast

Revenue Estimate
Dimed SA Distribuidora de Medicamentos

For the last 13 years the compound annual growth rate for Dimed SA Distribuidora de Medicamentos's revenue is 11%. The projected CAGR for the next 3 years is 15%.

11%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Dimed SA Distribuidora de Medicamentos

For the last 13 years the compound annual growth rate for Dimed SA Distribuidora de Medicamentos's operating income is 10%. The projected CAGR for the next 2 years is 26%.

10%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Dimed SA Distribuidora de Medicamentos

For the last 13 years the compound annual growth rate for Dimed SA Distribuidora de Medicamentos's net income is 8%. The projected CAGR for the next 2 years is 44%.

8%
Past Growth
44%
Estimated Growth
Estimates Accuracy
-27%
Average Miss
What are analyst estimates?

See Also

Summary
PNVL3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
PNVL3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PNVL3 stock valuation using valuation multiples.
Wall Street Estimates
PNVL3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PNVL3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PNVL3's stock price target?
Price Target
12.58 BRL

According to Wall Street analysts, the average 1-year price target for PNVL3 is 12.58 BRL with a low forecast of 12.12 BRL and a high forecast of 13.65 BRL.

What is Dimed SA Distribuidora de Medicamentos's Revenue forecast?
Projected CAGR
15%

For the last 13 years the compound annual growth rate for Dimed SA Distribuidora de Medicamentos's revenue is 11%. The projected CAGR for the next 3 years is 15%.

What is Dimed SA Distribuidora de Medicamentos's Operating Income forecast?
Projected CAGR
26%

For the last 13 years the compound annual growth rate for Dimed SA Distribuidora de Medicamentos's operating income is 10%. The projected CAGR for the next 2 years is 26%.

What is Dimed SA Distribuidora de Medicamentos's Net Income forecast?
Projected CAGR
44%

For the last 13 years the compound annual growth rate for Dimed SA Distribuidora de Medicamentos's net income is 8%. The projected CAGR for the next 2 years is 44%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 284,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.